Dr. Martin Ellinger is a scientific analyst in Morrison & Foerster’s Palo Alto office. His practice focuses on patent prosecution and counseling, with an emphasis in chemistry and life sciences.
Since joining the firm, Dr. Ellinger has participated in patent prosecution in the field of organic chemistry, with a particular technical emphasis on small molecule pharmaceuticals, polymers, formulations, and agricultural products. He has also provided support for a variety of due diligence projects, for example, Medivation’s acquisition of BioMarin’s phase III cancer drug, talazoparib, for $410 million upfront with another $160 million in milestones. Dr. Ellinger has worked with a wide range of clients, including startup biotech and chemistry companies, large pharmaceutical companies, and independent inventors.
Prior to joining Morrison & Foerster, Dr. Ellinger worked at Sanofi-Aventis as an industrial intern. His projects included investigating solvent replacement in an industrial-scale process for regulatory compliance.
Dr. Ellinger received his Diplôme d’Ingénieur (equivalent to an M.Sc.) in chemical sciences and engineering from École Nationale Supérieure de Chimie de Paris and an M.Sc. in organic chemistry from the Université Pierre et Marie Curie. He received his Ph.D. in chemistry from the University of California, San Diego. His doctoral research in the laboratory of Professor Guy Bertrand focused on developing stable versions of elusive octet-defying molecules (e.g., carbenes, nitrenes).
Dr. Ellinger is fluent in French.Show More